Felvizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	RSV
Clinical data
ATC code	none
Identifiers
CAS Number	167747-20-8^Y
ChemSpider	none
UNII	W9ZA2K5Q83
KEGG	D04136^Y
^NY (what is this?) (verify)

Felvizumab is a humanized monoclonal antibody against respiratory syncytial virus.^[1]^[2]

References

^ "WHO Drug Information" (PDF). Archived from the original (PDF) on February 23, 2012.
^ Milne GW (2018). "6591: Felvizumab". Drugs synonyms and properties. London: Routledge Revivals. ISBN 978-1-351-78989-9.

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Pemivibart Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Categories